NCCN Awarded $2 Million in Research Funding from Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies
The NCCN Oncology Research Program (ORP) was awarded a $2-million grant from Infinity Pharmaceuticals, Inc. to facilitate studies of duvelisib in the treatment of hematologic malignancies.
FORT WASHINGTON, PA - The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Infinity Pharmaceuticals, Inc. to evaluate the safety and effectiveness of duvelisib as a potential treatment for hematologic malignancies.
'NCCN ORP is plea...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news